Immunotherapy

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

By

Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.

Immunotherapy and the Future of Prostate Cancer Treatment

Immunotherapy and the Future of Prostate Cancer Treatment

By

Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

By

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

Attaching an Anticancer Payload to Platelets Shows Promise Against Postsurgical Recurrence

Attaching an Anticancer Payload to Platelets Shows Promise Against Postsurgical Recurrence

By

Researchers develop novel strategy for delivering immunotherapy agents to tumor surgical sites to eradicate tumor cells left behind after resection and reduce risk of recurrence.

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

By

The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.

New Targeted Therapy with a Double-Pronged Approach

New Targeted Therapy with a Double-Pronged Approach

By

A new targeted therapy approach may attack cancer on two fronts, boosting anti-tumor immune responses while also directly killing tumor cells .

New Use of an Old Drug Could Address Cancer Metastasis

New Use of an Old Drug Could Address Cancer Metastasis

By

CDK 4/6 inhibitors, currently approved for the treatment of estrogen-positive breast cancer, were found to inhibit metastasis in triple-negative breast

MABp1 Improves Symptoms vs Placebo in Colorectal Cancer

MABp1 Improves Symptoms vs Placebo in Colorectal Cancer

By

MABp1 (Xilonix) is an interleukin 1α-targeting antibody associated with antitumor activity and relief of debilitating symptoms in patients with advanced colorectal cancer. In this ongoing phase 3 clinical trial, its impact on other debilitating symptoms in this population was evaluated.

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

By

Because treatment with pertuzumab could include adverse events similar to those observed with EGFR antagonists, such as diarrhea, researchers evaluated participants from 3 trials to determine the incidence and severity of diarrhea observed with pertuzumab.

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

By

Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.

Topical Combination Reduces Actinic Keratosis Lesions, Reducing Risk of Squamous Cell Carcinoma

Topical Combination Reduces Actinic Keratosis Lesions, Reducing Risk of Squamous Cell Carcinoma

By

Study investigates the effectiveness of a topical treatment with an immune system-activator and a topical chemotherapy on actinic keratosis, a precursor to squamous cell carcinoma.

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

By

The efficacy and safety of atezolizumab in patients with previously treated NSCLC was evaluated in the OAK trial, an open-label, pivotal, phase 3 study, the results of which were recently published.

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

By

Results of the METLung trial are presented. In this trial, researchers evaluated the efficacy and safety of onartuzumab in patients with advanced NSCLC selected by MET immunohistochemistry.

Panitumumab Plus Accelerated RT Not Effective for Locoregionally Advanced HNSCC

Panitumumab Plus Accelerated RT Not Effective for Locoregionally Advanced HNSCC

By

Progression-free survival with panitumumab plus accelerated-fractionation radiotherapy was compared with that of cisplatin plus standard-fractionation radiotherapy in patients with locoregionally advanced HNSCC in a recently published study.

Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer

Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer

By

Patients with HER2-positive, HR-positive advanced breast cancer experience significantly improved progression-free survival when pertuzumab is added to first-line trastuzumab and an AI compared with trastuzumab and an AI alone, according to study findings presented at SABCS 2016.

Study Identifies Factors Associated With Outcomes After Dabrafenib + Trametinib

By

Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

By

Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

By

In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

By

Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

By

Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors. In this study, therefore, researchers sought to examine the incidence of neurotoxicity across anti-CTLA-4 and anti-PD-1 antibodies at a single institution.

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

By

The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous NSCLC.

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

By

Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

By

Treatment with pembrolizumab better maintained health-related quality of life compared with chemotherapy in patients with advanced melanoma refractory to ipilimumab.

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

By

Antibacterial prophylaxis with the flouroquinolone, ciprofloxacin, substantially reduced the risk of bacteremia and neutropenic fever in patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy and auto-HSCT.

Chemotherapy-Induced Dormancy Improves Immunotherapy for Breast Cancer

Chemotherapy-Induced Dormancy Improves Immunotherapy for Breast Cancer

By

Inducing quiescent dormancy with conventional chemotherapy makes cancer cells more susceptible to immunotherapy, thereby minimizing potential for tumor recurrence.

Managing IRAEs in Patients Receiving Checkpoint Inhibitors

Managing IRAEs in Patients Receiving Checkpoint Inhibitors

By

How should side effects of the new checkpoint inhibitor drugs be managed?

Experimental Drug Improves Immunotherapy Activity in Triple-Negative Breast Cancer

Experimental Drug Improves Immunotherapy Activity in Triple-Negative Breast Cancer

By

An experimental drug, AMPI-109, shows promise as an immunotherapy that sensitizes triple-negative breast cancer cells, enhancing the effectiveness of the drug.

Technique Maps Biomarkers That Predict Immunotherapy Response

Technique Maps Biomarkers That Predict Immunotherapy Response

By

With only 1 slide of a tumor section, an analysis of multiple tumor markers can be performed. The technique may help predict response to immunotherapy, which typically evokes responses in only a small group of patients.

Dual Antigen Targeting by CAR T Cells Improves Immunotherapeutic Technique

By

Chimeric antigen receptor (CAR) T cells may have improved therapeutic potential when they have 2 targets, according to preclinical findings using a mouse model.

Immunotherapy Combination is Effective in Colorectal Cancer

By

Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs